ATE500252T1 - Oxadiazolsubstituierte indazolderivate zur verwendung als sphingosin-1-phosphat (s1p) - agonisten - Google Patents
Oxadiazolsubstituierte indazolderivate zur verwendung als sphingosin-1-phosphat (s1p) - agonistenInfo
- Publication number
- ATE500252T1 ATE500252T1 AT08736315T AT08736315T ATE500252T1 AT E500252 T1 ATE500252 T1 AT E500252T1 AT 08736315 T AT08736315 T AT 08736315T AT 08736315 T AT08736315 T AT 08736315T AT E500252 T1 ATE500252 T1 AT E500252T1
- Authority
- AT
- Austria
- Prior art keywords
- sphingosine
- oxadiazole
- agonists
- phosphate
- indazole derivatives
- Prior art date
Links
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title 2
- -1 OXADIAZOLE-SUBSTITUTED INDAZOLE Chemical class 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0707617A GB0707617D0 (en) | 2007-04-19 | 2007-04-19 | Compounds |
| GB0805993A GB0805993D0 (en) | 2008-04-02 | 2008-04-02 | Compounds |
| PCT/EP2008/054647 WO2008128951A1 (en) | 2007-04-19 | 2008-04-17 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE500252T1 true ATE500252T1 (de) | 2011-03-15 |
Family
ID=39604751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08736315T ATE500252T1 (de) | 2007-04-19 | 2008-04-17 | Oxadiazolsubstituierte indazolderivate zur verwendung als sphingosin-1-phosphat (s1p) - agonisten |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8324254B2 (de) |
| EP (1) | EP2137181B1 (de) |
| JP (1) | JP5313229B2 (de) |
| KR (1) | KR20090130062A (de) |
| AR (1) | AR066095A1 (de) |
| AT (1) | ATE500252T1 (de) |
| AU (1) | AU2008240773B2 (de) |
| BR (1) | BRPI0809472A2 (de) |
| CA (1) | CA2684385A1 (de) |
| CL (1) | CL2008001099A1 (de) |
| CO (1) | CO6321136A2 (de) |
| CR (1) | CR11119A (de) |
| DE (1) | DE602008005285D1 (de) |
| DO (1) | DOP2009000237A (de) |
| EA (1) | EA016443B1 (de) |
| HK (1) | HK1138001A1 (de) |
| IL (1) | IL200870A (de) |
| JO (1) | JO2686B1 (de) |
| MA (1) | MA31311B1 (de) |
| MX (1) | MX2009011155A (de) |
| MY (1) | MY146606A (de) |
| NZ (1) | NZ579595A (de) |
| PE (1) | PE20090150A1 (de) |
| TW (1) | TWI408137B (de) |
| WO (1) | WO2008128951A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2453372T3 (es) | 2006-04-03 | 2014-04-07 | Astellas Pharma Inc. | Derivados de oxadiazol como agonistas de S1P1 |
| JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| JP2011506600A (ja) * | 2007-12-18 | 2011-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 自己免疫性障害および炎症性障害の治療において有用なテトラヒドロシクロペンタ［ｂ］インドール−３−イルカルボン酸誘導体 |
| DK2276759T3 (da) | 2008-04-04 | 2012-01-02 | Lilly Co Eli | 3-indazolyl-4-pyridylisothiazoler |
| GB0807910D0 (en) * | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| JP5449351B2 (ja) | 2008-07-23 | 2014-03-19 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 自己免疫障害および炎症性障害の処置において有用な置換型１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドル−３−イル）酢酸誘導体 |
| EP2307007B1 (de) * | 2008-07-23 | 2014-08-27 | Novartis AG | Sphingosin-1-phosphatrezeptormodulatoren und ihre verwendung zur behandlung von muskelentzündungen |
| ES2617868T3 (es) | 2008-08-22 | 2017-06-20 | Baxalta GmbH | Derivados de carbonato de bencilo poliméricos |
| PT2342205T (pt) | 2008-08-27 | 2016-07-28 | Arena Pharm Inc | Derivados de ácido tricíclico substituído como agonistas de recetor s1p1 úteis no tratamento de distúrbios autoimunes e inflamatórios |
| NZ592297A (en) | 2008-09-22 | 2012-11-30 | Cayman Chemical Co Inc | 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents |
| BRPI0923178A2 (pt) * | 2008-12-18 | 2016-02-16 | Merck Serono Sa | derivados heterocíclicos de oxadiazol fundidos úteis para o tratamento de esclerose múltipla |
| GB0910691D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| GB0910689D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| US8399451B2 (en) * | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| WO2011072488A1 (en) * | 2009-12-18 | 2011-06-23 | Glaxo Group Limited | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists |
| EP3378854B1 (de) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Verfahren zur herstellung von (r)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)essigsäure und salzen davon |
| US9085581B2 (en) | 2010-03-03 | 2015-07-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof |
| JP6209541B2 (ja) * | 2012-02-03 | 2017-10-04 | ノバルティス アーゲー | Ｎ−（４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシ）−アセトイミド酸エチルエステルの製造方法 |
| JP2016028016A (ja) * | 2012-12-12 | 2016-02-25 | 大日本住友製薬株式会社 | オキサジアゾール誘導体とその医薬用途 |
| JP6450315B2 (ja) * | 2013-08-20 | 2019-01-09 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | Ｓ１ｐ１受容体アゴニストの評価方法及びスクリーニング方法 |
| NZ734220A (en) | 2015-01-06 | 2022-01-28 | Arena Pharm Inc | Methods of treating conditions related to the s1p1 receptor |
| KR102603199B1 (ko) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염 |
| WO2018151834A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
| BR112020024762A2 (pt) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | métodos de tratamento de condições relacionadas ao receptor s1p1 |
| CN109100971B (zh) * | 2018-08-20 | 2024-02-09 | 合肥华耀电子工业有限公司 | 一种带互锁功能的开关机时序控制电路 |
| KR20210074291A (ko) | 2018-09-06 | 2021-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한 화합물 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3939238A1 (de) * | 1989-11-28 | 1991-05-29 | Bayer Ag | Heterocyclisch substituierte acrylsaeureester |
| US5262416A (en) * | 1990-01-28 | 1993-11-16 | Bayer Aktiengesellschaft | Pesticidal substituted 2-[6-(pyrimidinyl)-indol-1-yl]-acrylic esters |
| US5462943A (en) * | 1990-01-28 | 1995-10-31 | Bayer Aktiengesellschaft | Substituted acetic acid esters useful as pesticides per se and as intermediates for substitued acrylic esters pesticides |
| DE4002466A1 (de) * | 1990-01-28 | 1991-10-10 | Bayer Ag | Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester |
| US5523312A (en) * | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP2001199983A (ja) * | 2000-01-18 | 2001-07-24 | Teijin Ltd | ベンズイミダゾール誘導体 |
| WO2003105771A2 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| EP1622866B1 (de) * | 2003-04-30 | 2012-07-25 | Novartis AG | Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors |
| AU2004240586A1 (en) * | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists |
| AU2004277947A1 (en) * | 2003-10-01 | 2005-04-14 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists |
| EP1697333A4 (de) * | 2003-12-17 | 2009-07-08 | Merck & Co Inc | (3,4-disubstituierte)propansäurecarboxylate als agonisten des s1p (edg) rezeptors |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| WO2006047195A2 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| NZ560513A (en) * | 2005-02-25 | 2010-07-30 | Ono Pharmaceutical Co | Indole compound and use thereof |
| CN101146529B (zh) * | 2005-03-23 | 2012-08-29 | 埃科特莱茵药品有限公司 | 新颖噻吩衍生物作为鞘氨醇-1-磷酸酯-1受体激动剂 |
| AU2006240789B2 (en) | 2005-04-22 | 2010-03-04 | Daiichi Sankyo Company, Limited | Heterocyclic compound |
| MX2007015422A (es) * | 2005-06-08 | 2008-02-21 | Novartis Ag | Oxadiazoles o isoxazoles policiclicos y su uso como ligandos del receptor de s1p. |
| CA2619101A1 (en) * | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
| GB0601744D0 (en) * | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| ES2453372T3 (es) * | 2006-04-03 | 2014-04-07 | Astellas Pharma Inc. | Derivados de oxadiazol como agonistas de S1P1 |
| JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
-
2008
- 2008-04-17 PE PE2008000672A patent/PE20090150A1/es not_active Application Discontinuation
- 2008-04-17 TW TW097113880A patent/TWI408137B/zh not_active IP Right Cessation
- 2008-04-17 MX MX2009011155A patent/MX2009011155A/es active IP Right Grant
- 2008-04-17 CL CL200801099A patent/CL2008001099A1/es unknown
- 2008-04-17 NZ NZ579595A patent/NZ579595A/en not_active IP Right Cessation
- 2008-04-17 EA EA200970967A patent/EA016443B1/ru not_active IP Right Cessation
- 2008-04-17 AU AU2008240773A patent/AU2008240773B2/en not_active Expired - Fee Related
- 2008-04-17 BR BRPI0809472-1A patent/BRPI0809472A2/pt not_active IP Right Cessation
- 2008-04-17 JP JP2010503494A patent/JP5313229B2/ja not_active Expired - Fee Related
- 2008-04-17 AR ARP080101584A patent/AR066095A1/es not_active Application Discontinuation
- 2008-04-17 KR KR1020097021613A patent/KR20090130062A/ko not_active Application Discontinuation
- 2008-04-17 AT AT08736315T patent/ATE500252T1/de not_active IP Right Cessation
- 2008-04-17 JO JO2008183A patent/JO2686B1/en active
- 2008-04-17 WO PCT/EP2008/054647 patent/WO2008128951A1/en active Application Filing
- 2008-04-17 DE DE602008005285T patent/DE602008005285D1/de active Active
- 2008-04-17 MY MYPI20094368A patent/MY146606A/en unknown
- 2008-04-17 US US12/596,488 patent/US8324254B2/en not_active Expired - Fee Related
- 2008-04-17 CA CA002684385A patent/CA2684385A1/en not_active Abandoned
- 2008-04-17 EP EP08736315A patent/EP2137181B1/de not_active Not-in-force
-
2009
- 2009-09-10 IL IL200870A patent/IL200870A/en not_active IP Right Cessation
- 2009-10-08 DO DO2009000237A patent/DOP2009000237A/es unknown
- 2009-10-15 MA MA32280A patent/MA31311B1/fr unknown
- 2009-10-16 CO CO09115828A patent/CO6321136A2/es active IP Right Grant
- 2009-11-19 CR CR11119A patent/CR11119A/es not_active Application Discontinuation
-
2010
- 2010-04-29 HK HK10104250.5A patent/HK1138001A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008128951A1 (en) | 2008-10-30 |
| JP2010524886A (ja) | 2010-07-22 |
| IL200870A (en) | 2013-08-29 |
| IL200870A0 (en) | 2010-05-17 |
| HK1138001A1 (en) | 2010-08-13 |
| AR066095A1 (es) | 2009-07-22 |
| US8324254B2 (en) | 2012-12-04 |
| US20100113528A1 (en) | 2010-05-06 |
| AU2008240773A1 (en) | 2008-10-30 |
| MY146606A (en) | 2012-09-14 |
| JP5313229B2 (ja) | 2013-10-09 |
| KR20090130062A (ko) | 2009-12-17 |
| JO2686B1 (en) | 2013-03-03 |
| CA2684385A1 (en) | 2008-10-30 |
| PE20090150A1 (es) | 2009-05-08 |
| CR11119A (es) | 2010-01-18 |
| DOP2009000237A (es) | 2010-05-31 |
| DE602008005285D1 (de) | 2011-04-14 |
| NZ579595A (en) | 2012-06-29 |
| MA31311B1 (fr) | 2010-04-01 |
| MX2009011155A (es) | 2009-10-30 |
| TW200911794A (en) | 2009-03-16 |
| EP2137181B1 (de) | 2011-03-02 |
| EA016443B1 (ru) | 2012-05-30 |
| CL2008001099A1 (es) | 2008-10-24 |
| BRPI0809472A2 (pt) | 2014-09-09 |
| CO6321136A2 (es) | 2011-09-20 |
| AU2008240773B2 (en) | 2013-10-03 |
| EA200970967A1 (ru) | 2010-02-26 |
| EP2137181A1 (de) | 2009-12-30 |
| TWI408137B (zh) | 2013-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE500252T1 (de) | Oxadiazolsubstituierte indazolderivate zur verwendung als sphingosin-1-phosphat (s1p) - agonisten | |
| CY2020036I1 (el) | Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p | |
| CY2019027I1 (el) | Παραγωγα φωσφορου ως αναστολεις κινασης | |
| BRPI0818161A2 (pt) | composições que compreendem moduladores de receptores de esfingosina-1-fosfato (s1p) | |
| ZA200908624B (en) | 5-heteroaryl substituted indazoles as kinase inhibitors | |
| EP2268211A4 (de) | Instrument für minimalzugang | |
| DK2300459T3 (da) | Nye fenylpyrazinoner som kinasehæmmere | |
| EP2157859A4 (de) | Indazolverbindungen zur aktivierung von glucokinase | |
| BRPI0918846A2 (pt) | inibidores de cinase heterocíclica | |
| EP3978066C0 (de) | Systeme zur identifizierung eines zugangsanschlusses | |
| EP2170076A4 (de) | 4-carboxybenzylamino-derivate als histondeacetylase-hemmer | |
| BRPI0912855A2 (pt) | derivados de indazóis substituídos por fenila ou piridinila | |
| EP2176785A4 (de) | Techniken zur verwaltung von annotationstransformationen für kontextänderungen | |
| EP2214430A4 (de) | Zugangsüberprüfungsverfahren für ibss-netz | |
| BRPI0918602A2 (pt) | composto (i) | |
| BRPI0907963A2 (pt) | Derivados de indazola | |
| FI20080493A0 (fi) | Menetelmä hiilinielun mittaamiseksi | |
| DE502007001098D1 (de) | Vertikal geteilter Ausgleichbehälter für Kühlflüssigkeit | |
| DK2225233T3 (da) | Oxadiazolderivat med virkning på sphingosin-1-phosphat (s1p) | |
| BRPI0716778A2 (pt) | Derivados de tartarato para uso como inibidores do fator de coagulação ixa | |
| ITBS20070096A1 (it) | Dispositivo di sospensione per organi prensili | |
| IT1392058B1 (it) | Strumento operatorio, particolarmente per microchirurgia laringea | |
| FI20065394L (fi) | Menetelmät painolaadun hallintaan | |
| GB0722340D0 (en) | Sphingosine-1-phosphate (S1P) receptor compounds | |
| ZA200906256B (en) | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |